TEL AVIV, Israel, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 Financial Results and Cash Position
R&D Expenses: Research and development expenses were $0.9 million for the quarter ended June 30, 2017, compared to $1.9 million for the same period in 2016.
To read full press release, please click here.
